We are pleased to announce that at our annual general meeting (AGM) on Monday 29 November, all resolutions were duly passed. This includes each of the fundraising resolutions relating to the oversubscribed placing and open offer which was announced by the Company on 2 November 2021.
We are also pleased to announce that, in relation to the open offer, which closed for receipt of applications at 11.00 a.m. on 26 November 2021, we received valid applications, including excess applications, from qualifying shareholders for more than twice the number of open offer shares available.
Accordingly, the Company has raised approximately
You can find out more about the results of the AGM, open offer and issue of equity here
“We are delighted with the Company’s continued transformation – with Bleepa™ gaining momentum, securing its first commercial contract and significantly enhancing its offering, routes to market, scalability and security during the last year. Importantly, the rapid progress and significant developments since the period end highlight the scale of opportunity.
“We are now well funded to support accelerated revenue growth. The funds raised will enable Feedback to focus on further developing and rolling out Bleepa and CareLocker at pace, through targeted investment in sales and marketing and allow the Company to explore the NHS Community Diagnostic Centres and Indian tuberculosis opportunities in parallel, diversifying our strategic risk whilst capturing these important and timely opportunities.
“Using part of the proceeds of the Fundraising, the Company is planning to undertake a pilot scheme of the tuberculosis screening solution within some initial sites in
“In parallel, the Company is piloting the CDC (Community Diagnostic Centres) solution with Sussex ICS as one of the exemplar sites for the
“Reinforced with a new patient-centric cloud architecture and internationally recognised accreditations, Feedback is well placed to focus on driving international product deployment across public and private frameworks.
“We would like to thank existing and new shareholders for their support in the Fundraise as we build on the momentum achieved and develop new and exciting routes to market.”
Dr Tom Oakley, CEO